JN-International Medical Corporation - Vaccine Development

Vaccine Development

Meningococcal meningitis disease, also referred to as cerebrospinal meningitis is a contagious bacterial disease caused by Neisseria meningitidis bacteria. Meningococcal infections occur worldwide and are the only bacterial agents associated with epidemic meningitis in the meningitis belt of sub-Saharan Africa. With the culmination of several years of research, JN-International developed its vaccine for Meningococcal meningitis serogroups A, C, Y and W-135 (NmVac4-A/C/Y/W-135). The efficacy of the vaccine was tested in sub-Saharan Africa (Niger and Burkina Faso) using 750 people for a period of 56 months. Protective sero-conversion successfully occurred and was tested and recorded in vaccinated individuals during a spontaneous disease outbreak. However, it is well known that this type of vaccine gives disease protection for no more than 18 months. To better serve the market the company worked on and developed a Meningococcal meningitis serogroups A, C, Y and W-135 Diphtheria toxoid conjugate vaccine (NmVac4-A/C/Y/W-135 - DT), by using a genetically detoxified Diphtheria Toxoid as the protein carrier. This method has been shown to provide a minimum of 3 years protection. JNI’s conjugate meningococcal vaccine was tested in the Ivory Coast using 100 sero-negative male and female children and adults. Protective sero-conversion was recorded in 98% of the individuals as tested and recorded by the Pasteur Institute Côte d'Ivoire. JN-International is presently working to produce these vaccines in the United States. Production with regulatory approval for U.S. export is in process and will probably take a few years.

The research and development division of JN-International is in various stages for the development of vaccines for the prevention and cure of Hepatitis C Herpes Tuberculosis and a preventive and therapeutic vaccine for stroke.